Article
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.
Blood - 15 Dec 2004
Allan James M, Smith Alexandra G, Wheatley Keith, Hills Robert K, Travis Lois B, Hill Deirdre A, Swirsky David M, Morgan Gareth J, Wild Christopher P
Abstract excerpt
The xeroderma pigmentosum group D (XPD) gene encodes a DNA helicase that functions in nucleotide excision repair of chemotherapy-induced DNA damage, the efficiency of which is predicted to be affected by a lysine to glutamine variant at codon 751. We hypothesized that this constitutive genetic variant may modify clinical response to chemotherapy, and we have examined its association with outcome following...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.